Investment Thesis — Merit Medical Systems, Inc.
The market is overly focused on Merit Medical's recent underperformance and assumes its growth has structurally slowed, missing the company's accelerating share gains in high-margin interventional procedures. Investors are mispricing the durability of its recurring revenue streams and underestimating the operating leverage as hospital capex normalizes.
Catalysts
- Faster recovery in elective/interventional procedure volumes
- Successful launch and adoption of new high-margin products
- Hospital capex normalization boosting equipment sales
Risk Factors
- Prolonged hospital budget constraints delaying recovery
- Slower-than-expected adoption of new products
- Increased competitive pricing pressure compressing margins
Key Debates
MMSI's 17.31x Fwd P/E Expands to 22x by Q4 as Growth Validates Analyst PT
Gross Margin Expands 150bps by Q3 from Product Mix Shift
Forward Revenue Growth Accelerates to 8%+ by H2